2013-02-27 12:31:25 -

co.don AG /
co.don AG: positive business performance in 2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

co.don  AG,  one  of  the  leading  companies  in  the  production of autologous
cartilage  cell transplants for the treatment of articular and vertebral damage,
can  look back on a  positive financial year 2012. The  strategy of securing the
Germany  market - also as a reference for the planned international activities -
is succeeding. According to preliminary figures, revenue here rose by about 21%
(unaudited).  Including the sales performance  in foreign markets, total revenue
growth of around 16% to €2.7m was achieved in 2012 (unaudited).

Thanks    to the acquisition of  two new investors, co.don  AG received funding of
some  €3.9m. The  shareholders' meeting  adopted a  proposal from  the Executive
Board  and Supervisory  Board to  create new  approved capital of €3,554,292 and
authorised the Executive Board to increase existing share capital to €10,662,876
when the new approved capital is entered in the commercial register. The capital
increase was carried out in August 2012. The shareholders' meeting also passed a
resolution to expand the Supervisory Board from three to six members.

The  additional capital  will in  particular cover  the substantial expenses for
clinical  trials and therefore of applying for a central marketing authorisation
for  co.don AG's main product from the  European Medicines Agency (EMA). In June
2012 the  recruitment phase was successfully completed for the Phase II clinical
trial.  In December 2012 the full  set of approval documents  was filed with the
European  Medicines Agency in London. The product  can still be sold in Germany,
the  main  sales  market  for  co.don  AG,  until the marketing authorisation is
granted,  because  the  company  applied  for  the appropriate approval from the
national  German federal authority before the  deadline. At the same time co.don
AG is intensifying its marketing and sales activities in non-EU countries.

In  March 2012 co.don  AG was  the main  sponsor of  the First  Berlin Cartilage
Symposium. Some 120 physicians from Germany and abroad met to discuss the latest
developments,  current methods  and their  experiences of regenerative articular
surgery.  As the symposium was such a success, a second event will take place on
12 April 2013.

In  June 2012 the American patent  office granted co.don AG  a patent to produce
autologous  intervertebral  disc  cartilage  cell  transplants.  The company has
therefore  been able  to protect  its production  process in  one of the world's
largest sales markets for healthcare.

The  orthopaedic  department  of  the  Agaplesion  Elisabethenstift  hospital in
Darmstadt  became the first  clinic in Germany  to be recognised  as an official
teaching  centre  by  the  International  Cartilage Repair Society (ICRS). Since
2006 the  consultant Dr.  Thomas Schreyer  has applied  the method  developed by
co.don AG to treat cartilage damage in the knee joint.

"Joint  preservation  before  joint  replacement  -  over  5,000 knee and spinal
cartilage  patients have already been treated.  According to the experts who use
the  treatment, the success rate is  85%", explains Dr. Baltrusch, CEO of co.don
AG.  Compared with other therapy options the treatment is often much more gentle
and  in Germany the  costs are reimbursed  by both statutory  and private health
insurance.  Every year more than 175,000 knee replacement operations are carried
out  in Germany. "With our procedure", says co.don CEO, "cartilage damage can
be
repaired gently and replacement surgery often averted."

About co.don(®) AG:

The  company is  based in  Teltow, Brandenburg,  and was  founded in 1993. Since
2001 the  biopharmaceutical specialist  has been  listed on  the Frankfurt Stock
Exchange  (ISIN:  DE000A1K0227).  co.don  AG(®)  uses  tissue  engineering - the
cultivation  and  growth  of  autologous  tissue  cells  - to develop innovative
products and therapeutic concepts for the orthopaedic and neurosurgical markets.
The  cell-based  biological  drugs  (autologous  cell  transplants for articular
cartilage and intervertebral disks) are produced without the use of antibiotics,
growth  factors and genetic engineering. The  Executive Board of co.don(®) AG is
made up of Dr Andreas Baltrusch (CEO) and Ms Vilma Methner (COO, CSO).
Further information is available from: www.codon.de

Press contact
 co.don AG

 Matthias Meißner

 Warthestraße 21

 Tel:               0049 3328 43 46 37

 Fax:               0049 3328 43 46 43

 Email:             pr@codon.de



Press release (PDF): 
 hugin.info/132731/R/1681512/549765.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: co.don AG via Thomson Reuters ONE
[HUG#1681512]